Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|January 23, 2018
CDER Announces Guidance Documents for 2018
Author(s)Pharmaceutical Technology Editors
The FDA center released its list of planned guidance documents for the rest of the year.
Advertisement
FDA’s Center for Drug Evaluation and Research (CDER) released its planned 2018 agenda for guidance documents on Jan. 19, 2018. The center plans on publishing approximately 107 guidance documents this year discussing topics ranging from advertising, clinical, development, safety, approval submissions, generics, labeling, and more.
Specific topics to be addressed by CDER this year include biomarker qualification, postmarket safety reporting, electronic regulatory submissions, drug master files, CMC approval requirements, opioid products, rare diseases, and user fees.
The agency also has a variety of guidance documents addressing generic drugs and abbreviated new drug applications. Exclusivity, topical patches, and bioequivalence studies are some of the generic drug topics discussed.
The full list of planned guidance documents can be found on
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement